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Abstract: The emergence of precision medicine from the development of Poly (ADP-ribose) polymerase (PARP) inhibitors that preferentially kill cells defective in homologous recombination has
sparked wide interest in identifying and characterizing additional DNA repair enzymes that are
synthetic lethal with HR factors. DNA polymerase theta (Polθ) is a validated anti-cancer drug target
that is synthetic lethal with HR factors and other DNA repair proteins and confers cellular resistance
to various genotoxic cancer therapies. Since its initial characterization as a helicase-polymerase
fusion protein in 2003, many exciting and unexpected activities of Polθ in microhomology-mediated
end-joining (MMEJ) and translesion synthesis (TLS) have been discovered. Here, we provide a short
review of Polθ‘s DNA repair activities and its potential as a drug target and highlight a recent report
that reveals Polθ as a naturally occurring reverse transcriptase (RT) in mammalian cells.


Citation: Chen, X.S.; Pomerantz, R.T.

Keywords: DNA polymerase; reverse transcriptase; RNA; reverse transcription; double-strand break
repair; translesion synthesis

DNA Polymerase θ: A Cancer Drug
Target with Reverse Transcriptase
Activity. Genes 2021, 12, 1146.
https://doi.org/10.3390/

1. Introduction
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Mutations in homologous recombination (HR) genes BRCA1 and BRCA2 are strongly
predisposed to breast and ovarian cancer [1–6]. Since BRCA deficient cancer cells are impaired in HR, they are highly susceptible to DNA damage compared to normal cells [4,5].
Drugs that cause DNA damage or inhibit DNA repair, such as Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors, can therefore cause synthetic lethality in BRCA deficient cells
while sparing normal cells [4,7–9]. Highly anticipated PARP inhibitors (PARPi), however,
lead to drug resistance, which often causes patient mortality [7,10–12]. Thus, it remains
important to identify and develop alternative drug targets involved in DNA repair for
BRCA deficient cancers that reduce drug resistance and potential side effects.
Studies performed in 2015 identified the multi-functional DNA repair protein DNA
polymerase θ (Polθ) as a promising drug target in HR-deficient cancers [13,14]. Polθ is
upregulated in the majority (70%) of breast tumors and epithelial ovarian cancers [14–18],
and its overexpression correlates with HR defects and a poor clinical outcome [14–16,19].
Polθ also confers resistance to ionizing radiation, genotoxic chemotherapy drugs (e.g.,
topoisomerase inhibitors, cisplatin), and PARPi [14,20–23]. Thus, in addition to promoting
the proliferation of HR deficient cells, Polθ’s DNA repair activities, such as microhomologymediated end-joining (MMEJ) of double-strand breaks (DSBs), contribute to cellular resistance of a variety of genotoxic anti-cancer agents.
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2. Overview of Polθ DNA Repair Activities
Polθ is a large multi-functional protein containing an N-terminal superfamily 2 (SF2)
helicase (Polθ-hel) [24], an unstructured central domain, and a C-terminal A-family polymerase domain (Polθ-pol) that is structurally similar to bacterial Pol I enzymes, such as
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are also deficient in proofreading [35].
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Polθ additionally facilitates DSB repair via MMEJ—also referred to as alternative endjoining (alt-EJ) and polymerase theta mediated end-joining (TMEJ) (Figure 1C) [13,21,25,36–38].
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out or strongly suppress the expression of Polθ, which is equivalent to simultaneous inactivation of both enzymatic domains (https://depmap.org/portal/ccle/ accessed on 1 May
2021) [13,14,51,58]. The development of a proteolysis targeting chimera (PROTAC) [59–
61] degrader of Polθ therefore, represents a plausible therapeutic option since this would
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The development of a proteolysis targeting chimera (PROTAC) [59–61] degrader of Polθ
therefore, represents a plausible therapeutic option since this would fully abolish all of
Polθ activities.
4. Polθ as a Reverse Transcriptase
Considering that Polθ definitively functions in MMEJ and TLS pathways and suppressing mitotic crossovers and has been implicated in anti-recombination activity and base
excision repair, the question arises whether it exhibits additional DNA repair activities that
contribute to cancer cell proliferation. A curious characteristic of Polθ-pol is its deficient
proofreading function due to acquired mutations (Figure 1A). Pols lacking exonuclease
activity typically exhibit low-fidelity DNA synthesis, and in some cases, this enables TLS
activity. Interestingly, inactivating the 30 –50 exonuclease activity of some related A-family
bacterial Pol I enzymes allows these polymerases to reverse transcribe RNA like retroviral
reverse transcriptases (RTs), which lack proofreading activity [62,63]. Because Polθ is a
highly error-prone enzyme that can utilize various double-strand and ssDNA substrates
and is void of exonuclease activity such as retroviral RTs, we examined in recent studies
whether Polθ-pol can additionally utilize RNA as a template and thus act as an RT [64]. To
determine whether Polθ-pol performs RNA-dependent DNA synthesis activity, we chose a
biochemical approach. Our studies utilizing radio-labeled DNA/RNA primer templates
found that Polθ-pol exhibits robust RT activity, similar to retroviral RTs (Figure 5A) [64].
Notably, Polθ-pol did not require any specific reaction or buffer conditions and performed
RNA-dependent DNA synthesis activity on various template constructs and sequences,
and its RT activity mimicked retroviral RTs, such as those expressed by Human Immunodeficiency Virus (HIV), Avian Myeoloblastosis Virus (AMV), and Moloney Murine Leukemia
Virus (M-MulV). Most remarkably, our recent report found that Polθ-pol exhibits a higher
fidelity and velocity of 20 -deoxyribonucleotide incorporation on RNA versus DNA [64].
This suggests the enzyme was selected to be more accurate and efficient on RNA. In contrast to Polθ-pol, all other recombinant human Pols from the A, X, and B families failed
to show any RT activity. Y-family Pols κ and η, however, showed minimal RT activity,
resulting in the addition of only a few nucleotides on RNA under identical conditions as
Polθ-pol and HIV RT, which fully extended DNA/RNA primer-templates.
To probe the mechanism by which Polθ-pol uniquely accommodates DNA/RNA
hybrids, we utilized X-ray crystallography to solve the ternary structure of Polθ-pol on a
DNA/RNA primer-template with incoming 20 ,30 -dideoxyguanosine triphosphate (ddGTP).
Remarkably, the 3.2 Å structure of the Polθ-pol:DNA/RNA:ddGTP complex revealed
that the thumb domain undergoes a major structural rearrangement to accommodate
the DNA/RNA hybrid when compared to the previously solved structures of Polθ-pol
binding to a DNA/DNA primer-template (Figure 6A–C) [26]. For example, 57% of residues
within this subdomain, which interacts with the hybrid double-helix region five base-pairs
upstream from the 30 primer terminus, undergo conformational changes from helices to
loops (Figure 6B). This partial refolding of the thumb domain may be needed to provide the
necessary interactions with the DNA/RNA hybrid that is wider than B-form DNA/DNA
and takes a slightly different orientation in its interaction with the polymerase (Figure 6B).
The 12 Å shift observed for residue K2181 highlights the dramatic reconfiguration of the
thumb subdomain (Figure 6D). In contrast to the two previously solved structures of
Polθ-pol:DNA/DNA:ddGTP complexes, which were in the closed configuration, our Polθpol:DNA/RNA:ddGTP complex was captured in the open configuration. Thus, the O-helix
in the fingers subdomain is rotated outward, and the incoming ddGTP substrate is partially solvent-exposed (Figure 6C). The open to closed conformational change upon dNTP
binding by A-family Pols on DNA/DNA has been extensively characterized by many laboratories and continues to provide intriguing mechanistic insight into these highly conserved
enzymes [65–69]. Another notable shift observed in the Polθ-pol:DNA/RNA:ddGTP complex includes residue E2246 (palm subdomain), which appears to form a specific ribose
20 -hydroxyl interaction with the RNA template (Figure 6E). Additional multiple hydrogen
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Being that multiple studies suggest RNA-mediated DNA repair as a potential mechanism of DNA repair in eukaryotic cells [75–77], our findings suggest a plausible function for
Polθ in tolerating ribonucleotides during DNA repair. In one scenario, unrepaired ribonucleotides at or near DSB ends can serve as template bases during DNA repair synthesis by
Polθ during MMEJ (Figure 5B). The possibility also exists that Polθ utilizes ribonucleotides
during TLS (Figure 5C). In support of this idea, ribonucleotides are the most frequently
occurring lesion in eukaryotic genomes as a result of their misincorporation by replicative
Pols [78]. Thus, in the event that genome embedded ribonucleotides are not efficiently
repaired, such as in RNASEH2 deficient cells, replication forks are likely to become arrested.
This is owing to the fact that replicative Pols are unable to tolerate template ribonucleotides
and stall upon encountering these lesions [78,79]. In this scenario, TLS would be a desirable
outcome, especially if the ribonucleotide lesions can be replicated accurately. Although
future studies will be needed to test Polθ TLS activity opposite genome-embedded ribonucleotides in cells, the enzyme’s ability to easily accommodate A-form DNA/RNA hybrids
relative to other Pols reveals its unique and extraordinary structural plasticity. Hence,
it will be interesting to determine whether similar structural rearrangements within the

pears to form a specific ribose 2′-hydroxyl interaction with the RNA template (Figure 6E).
Additional multiple hydrogen bonds are observed between the 2′-hydroxyl group of the
RNA template and Thr/Gln residues of Polθ-pol (Figure 6F). Polθ residue Y2391 also
forms a hydrogen bond with the template ribonucleotide that pairs with the incoming
ddGTP (Figure 6G). Similar hydrogen bonds are observed in structures of retroviral RTs,
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Our studies also confirmed the ability of Polθ to utilize ribonucleotide template bases
during its DNA repair activities in cells. For instance, we utilized a newly developed
MMEJ GFP reporter assay in which MMEJ activity results in activation of a linear GFP
expression vector [20]. To probe Polθ RNA-dependent DNA synthesis activity in cells, the
GFP reporter was modified to include multiple ribonucleotides adjacent to the microhomology tract (Figure 5B). Here, activation of the GFP expression vector required RNAdependent DNA repair synthesis activity during MMEJ. Our studies clearly showed that
the inactivation of Polθ via CRISPR-Cas9 genetic engineering resulted in a significant re-
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5. Conclusions and Perspectives
The continued and growing interest in Polθ biology and drug development is expected
to lead to many exciting discoveries regarding the respective activities of Polθ helicase
and polymerase, as well as inform the development of improved therapeutics targeting
this multi-functional enzyme. The recent report on Artios Pharma’s allosteric Polθ-pol
inhibitor class demonstrates for the first time that this specific domain of Polθ is indeed
druggable. Another recent study indicates that the helicase domain is also druggable. Here,
the authors re-purposed the antibiotic Novabiocin as a Polθ-hel inhibitor that exhibited
high micromolar IC50 . Further development of potent and selective Polθ-hel inhibitors will
be needed to fully assess the potential of this domain as a drug target in HR-deficient cells.
As with all early-stage drugs, it remains to be seen whether Polθ-pol or Polθ-hel inhibitors
will lead to clinically effective therapeutics. Notably, decades of drug development research
targeting HIV RT and other viral polymerases demonstrate the successful development
of selective and potent inhibitors against these polymerases, including both competitive
nucleoside prodrugs and allosteric non-nucleoside drug inhibitors [80–84]. For example,
the prodrug nucleotide analog remdesivir was recently approved for emergency use against
Sars-Cov-2 RNA polymerase [85,86]. Clinical grade drug development against human
DNA helicases, however, has yet to be achieved. However, considering that the ATP
binding pocket within Polθ-hel is well defined and solvent-exposed like kinases [24], this
domain will likely be a viable drug target for clinical-grade candidates specifically designed
as Polθ-hel inhibitors.
A major question that arises from the recent research published by Chandramouly et al.
is whether Polθ’s RT activity specifically contributes to particular DNA repair functions,
such as cellular tolerance to genome embedded ribonucleotides. Separation of function
mutations may be needed to pursue such questions. Considering that Polθ’s RT activity
appears to be similar to HIV and other retroviral RTs, a question that arises is whether
HIV RT nucleoside inhibitors may be useful for targeting Polθ DNA synthesis activity in
cells, and thus, can potentially be re-purposed as anti-cancer agents. Indeed, Polθ and
other A-family Pols with a conserved tyrosine residue within the fingers subdomain are
known to be inhibited by 20 ,30 ,-dideoxyribonucleoside triphosphates (ddNTPs) [27]. Thus,
it would be interesting to determine the effects of nucleoside prodrug inhibitors of HIV RT
on Polθ cellular activities and the survival of HR-deficient cells. For instance, prodrugs
such as zalcitabine and didanosine are converted by nucleoside/nucleotide kinases into
their respective active metabolites, ddCTP and ddATP, which inhibit Polθ. The clinical
impact of such nucleoside analogs, however, may be limited due to their modest potency
and cross-reactivity against mitochondrial Polγ and possibly other Pols. Nevertheless,
based on the successful history of competitive nucleotide inhibitors of viral polymerases,
the possibility exists that potent and selective nucleotide analog inhibitors of Polθ-pol can
be developed in addition to allosteric inhibitors. Regardless of their mechanism of action,
the continued development of Polθ-pol and Polθ-hel drug-like inhibitors is expected to
generate a lot of excitement for both the translational and basic research communities.
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